Advertisement
News
Advertisement

Patient dies in Biogen MS drug trial

Tue, 10/19/2010 - 11:32am
Mass High Tech: The Journal of New England Technology

In a Phase 2 clinical trial, Biogen Idec and Roche reported their multiple sclerosis treatment, ocrelizumab, showed signs of reducing the disease indications – but they also reported that one patient died during the testing.

The drug, developed for patients with relapsing-remitting multiple sclerosis, showed a reduction in the number of flare-ups in a year and a reduction in brain lesions.

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading